NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALDOMET (methyldopate hydrochloride) is an injectable antihypertensive agent approved in 1962 for managing hypertension. It is a centrally-acting alpha-2 adrenergic agonist that lowers blood pressure by reducing sympathetic nervous system activity. This product represents a legacy therapeutic with established clinical utility in acute hypertensive management.
LOE Approaching
As a legacy injectable with LOE approaching, this product likely operates with a small, maintenance-focused commercial team managing existing utilization rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ALDOMET offers limited entry-level career opportunity (0 linked jobs) but provides valuable experience in lifecycle management, legacy product stewardship, and cost-containment strategy for a Merck asset. Roles focus on maintaining existing market position and managing compliance rather than growth initiatives.
Medical AffairsRegulatory Affairs
Worked on ALDOMET at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.